Table 1 Clinical characteristics and hemodynamics of PH patients.

Functional status,

   NYHA functional class II, III, IV (n)

30, 51, 20

   6MWD (predicted), m

443 ± 142 (589 ± 102)

   Dyspnoe score (Borg index)

4 ± 2

Diagnosis (n)

   Idiopathic PAH

41

   Familial PAH

9

   PAH associated with

Systemic sclerosis

27

Portal hypertension

1

HIV

2

   Chronic thromboembolic pulmonary hypertension

21

Treatment† (n)

   Bosentan

17

   Bosentan + Sildenafil

15

   Epoprostenol

13

   Sildenafil

7

   Epoprostenol + Sildenafil

7

   Sitaxentan

5

   Sildenafil + Sitaxentan

4

   Treprostinil + Bosentan + Sildenafil

3

   Epoprostenol + Sildenafil + Bosentan

3

   Treprostinil + Sitaxentan

2

   Calcium Antagonist

2

   Bosentan + Epoprostenol

2

   Treprostinil + Sildenafil

1

Hemodynamics

   Heart rate, beats/min

79 ± 13

   Mean pulmonary artery pressure, mmHg

46 ± 16

   Mean right atrial pressure, mmHg

6 ± 4

   Pulmonary capillary wedge pressure, mmHg

8 ± 4

   Pulmonary vascular resistance, dyn.s/cm5

632 ± 370

   Cardiac output, l/min

5,5 ± 1,9

   Cardiac index, l/min/m²

3,0 ± 0,9

   Mixed venous O₂ saturation, %

67 ± 9

Cardiopulmonary exercise testing*

   VO_2,peak (ml/min)

1039 ± 544

   VO_2,peak-predicted (%)

46.0 ± 20.7